Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Wednesday reported first-quarter adjusted earnings of $9.47 per share, up 15% year-over-year, beating the consensus of $8.89.
The company reported sales of $3.61 billion, up 19% year over year, beating the consensus of $3.48 billion.
Eylea HD Growth Driven By Demand, Pricing Pressure Persists
In the quarter, Eylea HD sales increased 52% to $468 million, driven by higher sales volumes and increased demand, partly offset by a lower net selling price.
In addition, Eylea HD net product sales were negatively affected by lower wholesaler inventory levels at the end of the first quarter of 2026 than at the end of the fourth quarter of 2025.
Eylea HD net product sales decreased 7% sequentially; however, physician unit demand increased 10% sequentially.
data-variant=”card”
data-news-mode=”manual”
>